The FDA granted fast track designation to FLQ-101 for the treatment of retinopathy of prematurity, according to a press release from FELIQS.
FLQ-101 is a once-daily oral and intravenous solution designed to mitigate inflammation and abnormal neovascularization in the retina by spurring the physiologic response of vascularization. The FDA’s ruling will expedite the review process for treatments that show promise in addressing unmet needs in severe conditions.
FLQ-101 received orphan drug designation earlier this year, and the company is preparing to begin a phase 1b/2 study of the